-
1.发明公开COMPOSITIONS AND METHODS FOR SELECTIVE DISSOLUTION OF NASCENT INTRAVASCULAR BLOOD CLOTS 审中-公开组合物和新兴血管内血栓的选择性终止方法
公开(公告)号：EP1648497A2
公开(公告)日：2006-04-26
申请号：EP04777178.7
申请日：2004-06-28
CPC分类号： A61K9/0019 , A61K35/18 , A61K38/49
摘要： Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots, which are capable of selective dissolution of pathological nascent clots formed intravascularly, with minimal risk of unwanted dissolution of pre-existing hemostatic clots, are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.
-
2.发明公开COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF UNCONTROLLED FORMATION OF INTRAVASCULAR FIBRIN CLOTS 审中-公开组合物以及预防和治疗方法血管内纤维蛋白凝块暴力的形成。
公开(公告)号：EP1093378A4
公开(公告)日：2001-10-10
申请号：EP99921945
申请日：1999-05-12
申请人： UNIV PENNSYLVANIA
IPC分类号： A61K45/00 , A01N63/00 , A61K38/16 , A61K38/17 , A61K38/46 , A61K38/49 , A61P7/02 , C12N5/08 , C12N9/70 , A61K38/00 , A61K35/18 , A61K38/43 , A61K38/48 , A61K38/54 , A61K47/42
CPC分类号： A61K38/49 , A61K35/18 , A61K38/166 , A61K38/177 , A61K2300/00
摘要： Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.
摘要翻译： 用于预防和治疗不受控制的血管内形成纤维蛋白凝块的组合物和方法提供了worin纤溶或抗凝药物biocompatibly耦合到红血细胞的载体。
-
公开(公告)号：EP0701606A4
公开(公告)日：1999-06-30
申请号：EP94915405
申请日：1994-04-22
发明人： GARFINKEL LEONARD , GORECKI MARIAN , PANET AMOS
IPC分类号： C12N15/09 , A61K31/60 , A61K31/715 , A61K38/00 , A61K38/37 , A61K38/46 , A61K38/49 , A61P7/02 , A61P9/00 , C07K14/755 , C12N9/64 , C12P21/02 , C12R1/19 , A61K38/43 , A61K38/48 , C12N9/70 , C12N9/72
CPC分类号： C07K14/755 , A61K38/37 , A61K38/49 , A61K31/60 , A61K2300/00
摘要： A method is provided for the use of a fragment of von Willebrand Factor (vWF) comprising the platelet glycoprotein Ib (GPIb) binding domain in conjunction with known therapies to obtain enhanced protection against thrombosis, improved thrombolysis, and a decreased likelihood of reocclusion following thrombolytic treatment. Additionally, a method is provided for the use of the vWF fragment and aspirin to prevent complications following traumatic vascular damage.
-
公开(公告)号：EP0489836A4
公开(公告)日：1993-05-26
申请号：EP90913585
申请日：1990-08-27
申请人： DUKE UNIVERSITY
发明人： PORTER, NED, A. , BRUHNKE, JOHN, D.
IPC分类号： A61K38/43 , A61K38/48 , C07C205/43 , C07C205/45 , C07C205/56 , C07C229/44 , C07C257/18 , C07C279/18 , C07C323/56 , C12N9/00 , C12N9/50 , C12N9/64 , C12N9/74 , C12N13/00 , C07D211/26 , C07D211/30 , C07D211/56 , C07D211/98 , C12N9/68 , C12N9/70 , C12N9/76
CPC分类号： C12N9/6429 , C07C205/43 , C07C205/56 , C07C229/44 , C07C257/18 , C12N9/00 , C12N9/50 , C12N13/00 , C12Y304/21005
摘要： Light activated acyl-enzymes of formula (III) are disclosed. In the compounds of formula (III) ENZ is an enzyme, X is O or S, Y is -NR3R4, -OR5, or -SR5, and Z is a nucleophile; m is 0 to 3 and n is 1 or 2; Y is substituted on the ring at either or both of the 4 and 6 position. R1 and R2 are each independently H, C1 to C4 alkyl, C3 to C4 unconjugated alkenyl, or C3 to C4 unconjugated alkynyl. R3 and R4 are each independently H, C1 to C4 alkyl, C3 to C4 unconjugated alkenyl, or C3 to C4 unconjugated alkynyl, except that R3 and R4 are not simultaneously both H. R5 is C1 to C4 alkyl, C3 to C4 unconjugated alkenyl, or C3 to C4 unconjugated alkynyl. Methods of using the acyl-enzymes and intermediates for making the acyl-enzymes are disclosed. A preferred intermediate is 2-propenoic acid, 3-(2-hydroxy-4-diethylaminophenyl)-2-methyl-, 4-(aminoiminomethyl)phenyl ester, (E)-, monohydrochloride salt, which is preferably reacted with thrombin to form an acyl-thrombin.
摘要翻译： 公开了式（III）的光活化酰基 - 酶。 在式（III）化合物中，ENZ是酶，X是O或S，Y是-NR3R4，-OR5或-SR5，并且Z是亲核试剂; m为0至3且n为1或2; Y在4位和6位中的任一个或两个上在环上被取代。 R1和R2各自独立地为H，C1-C4烷基，C3-C4非共轭烯基或C3-C4非共轭炔基。 R3和R4各自独立地为H，C1-C4烷基，C3-C4非共轭烯基或C3-C4非共轭炔基，除了R3和R4不同时为H。R5为C1-C4烷基，C3-C4非共轭烯基， 或C3至C4未连接的炔基。 公开了使用酰基 - 酶和中间体制备酰基 - 酶的方法。 优选的中间体是2-丙烯酸，3-（2-羟基-4-二乙基氨基苯基）-2-甲基 - ，4-（氨基亚氨基甲基）苯基酯，（E） - 一盐酸盐，其优选与凝血酶反应以形成 一种酰基凝血酶。
-
5.发明公开METHODS AND MATERIALS FOR EXPRESSION OF HUMAN PLASMINOGEN IN A EUKARYOTIC CELL SYSTEM 失效用于在真核细胞系统中表达人血管生成素的方法和材料
公开(公告)号：EP0467987A4
公开(公告)日：1992-07-08
申请号：EP90907737
申请日：1990-04-26
发明人： CASTELLINO, FRANCIS, J. , WHITEFLEET-SMITH, JOANN, L. , ROSEN, ELLIOT, D. , MCLINDEN, JAMES, H.
IPC分类号： A61K38/48 , A61K38/00 , A61K38/46 , A61K38/54 , A61P7/02 , C07K14/00 , C07K14/315 , C07K16/18 , C07K16/40 , C07K19/00 , C12N9/68 , C12N9/70 , C12N9/99 , C12N15/09 , C12N15/12 , C12N15/85 , C12N15/866 , C12N15/00 , C12N7/01 , C12N9/96 , C12N15/52
CPC分类号： C12N15/86 , A61K38/00 , C07K14/3153 , C07K16/18 , C07K16/40 , C12N9/6435 , C12N9/99 , C12N15/85 , C12N2710/14143 , C12Y304/21007
摘要： Recombinant human plasminogen may be produced in invertebrate cells or in other eukaryotic cells lacking a site-specific plasminogen activator by expression of a vector including a gene encoding human plasminogen. Human plasminogen may thus be expressed without degradation by plasmin produced by intracellular plasminogen activators found in mammalian cells. The plasminogen product of such expression may be purified, acylated, complexed with acylated or non-acylated fibrinolytic enzymes and formulated into pharmaceutical compositions for use in thrombolytic therapy.
-
公开(公告)号：EP0411031A4
公开(公告)日：1992-02-05
申请号：EP89905249
申请日：1989-03-31
发明人： FEARON, DOUGLAS, T. , KLICKSTEIN, LLOYD, B. , WONG, WINNIE, W. , CARSON, GERALD, R. , CONCINO, MICHAEL, F. , IP, STEPHEN, H. , MAKRIDES, SAVVAS, C. , MARSH, HENRY, C., JR.
IPC分类号： A61K38/00 , A61K20060101 , A61P7/02 , A61P9/00 , A61P9/10 , A61P29/00 , A61P37/00 , A61P37/06 , C07H20060101 , C07H21/04 , C07K1/18 , C07K1/22 , C07K14/00 , C07K14/315 , C07K14/705 , C07K14/715 , C07K16/28 , C12N1/21 , C12N5/10 , C12N9/70 , C12N9/72 , C12N15/09 , C12N15/12 , C12P20060101 , C12P21/00 , C12P21/02 , C12R1/19 , C12R1/91 , C07H15/12 , C07K3/20 , C07K7/10 , C12N1/20 , C12N5/00
CPC分类号： C07K16/2896 , A61K38/00 , C07K14/3153 , C07K14/70596
-
7.发明公开Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them 失效酶衍生物，用于处理含有相同其制备方法和药物组合物。
公开(公告)号：EP0091240A2
公开(公告)日：1983-10-12
申请号：EP83301651.2
申请日：1983-03-24
申请人： BEECHAM GROUP PLC
CPC分类号： C12N9/6459 , A61K38/00 , C07K14/3153 , C12N9/96 , C12Y304/21069
摘要： A derivative of streptokinase-human plasminogen activator complex in which the active catalytic site essential for fibrinolytic activity is blocked by a 2- or 4-aminobenzoyl group, is useful in treating venous thrombosis.
The blocking group is removable by hydrolysis such that the first order rate is in the range 0.7 x 10 -5 sec -1 to 2.5 x 10 -5 sec -1 in isotonic aqueous media at pH 7.4 at 37-
公开(公告)号：EP0028489B1
公开(公告)日：1983-10-05
申请号：EP80303797.7
申请日：1980-10-27
申请人： BEECHAM GROUP PLC
CPC分类号： C07K14/3153 , A61K38/00 , C12N9/99 , Y10S514/802
-
9.发明公开A METHOD FOR PRODUCING N-TERMINAL METHIOINE FREE POLYPEPTIDES IN MICROBIAL HOST CELLS 审中-公开用于生产多肽不具有N-末端甲硫氨酸的微生物宿主细胞
公开(公告)号：EP2097520A4
公开(公告)日：2012-07-04
申请号：EP07706183
申请日：2007-01-12
申请人： BIOCON LTD
发明人： SASTRY KEDARNATH , SRIRAM AKUNDI VENKATA , GOEL ANUJ , KAMATH SANDEEP VISHWANATH , VALERA HARDIK , GARG MAYANK KUMAR , SREENIVAS SUMA , SWETHA MALUR DATTATREYA , BASU AMRITA , RAGHUNANDAN REENA NICHINMETLA
CPC分类号： C12P21/02 , A61K38/27 , C07K14/3153 , C07K14/395 , C07K14/61 , C07K2319/35 , C07K2319/50 , C12N9/52 , C12P21/06
摘要： A method of making N-terminal methionine free polypeptide in a recombinant microbial host cell and pharmaceutical compositions along with one or more pharmaceutical excipients for management of various therapeutic disorders. Specifically, the invention relates to the production of N-terminal methionine free Streptokinase or human growth hormone by co expression with a protease enzyme in E.coli.
-
10.发明授权PROCESS FOR PRODUCING STREPTOKINASE USING GENETICALLY MODIFIED ESCHERICHIA COLI 有权用于生产链激酶通过培育基因改造大肠杆菌
-
-
-
-
-
-
-
-
-
搜索结果
55 条记录 (耗时 0.024 秒)
